| Browse All

Cingulate Inc. (CINGW)

Kansas City, United States | NasdaqCM
0.03 USD +0.01 (30.667%) ⇧ (April 21, 2026, 9:34 a.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:53 a.m. EDT

Severe fundamental distress indicated by massive losses, unsustainable debt, and recent executive legal issues; the price data shows erratic volatility with a sharp decline to $0.02, reflecting a high probability of bankruptcy or dilution via the reported ATP sales.

None
Attribute Value
Debt to Equity Ratio 350.214
Beta -0.77
Website https://www.cingulate.com

Info Dump

Attribute Value
Address1 1,901 West 47th Place
Ask 0.0
Ask Size 0
Beta -0.765
Bid 0.0
Bid Size 0
Book Value 0.346
City Kansas City
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.0294
Current Ratio 1.164
Custom Price Alert Confidence HIGH
Day High 0.0294
Day Low 0.0212
Debt To Equity 350.214
Display Name Cingulate
Ebitda -19,397,214
Ebitda Margins 0.0
Eps Trailing Twelve Months -1.732
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 0.0294
Fifty Two Week High Change 0.0
Fifty Two Week High Change Percent 0.0
Fifty Two Week Low 0.0212
Fifty Two Week Low Change 0.008200001
Fifty Two Week Low Change Percent 0.3867925
Fifty Two Week Range 0.0212 - 0.0294
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 11,292,081
Free Cashflow -10,425,198
Full Exchange Name NasdaqCM
Full Time Employees 14
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -9,774,057
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,021-12-08
Language en-US
Long Business Summary Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Long Name Cingulate Inc.
Market us_market
Market State REGULAR
Max Age 86,400
Message Board Id finmb_1674914781
Net Income To Common -22,449,912
Open 0.0385
Operating Cashflow -17,245,182
Operating Margins 0.0
Phone 913 942 2300
Previous Close 0.0225
Price Hint 4
Price To Book 0.0849711
Profit Margins 0.0
Quick Ratio 1.064
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0068999995
Regular Market Change Percent 30.666662
Regular Market Day High 0.0294
Regular Market Day Low 0.0212
Regular Market Day Range 0.0212 - 0.0294
Regular Market Open 0.0385
Regular Market Previous Close 0.0225
Regular Market Price 0.0294
Regular Market Time 1,776,778,486
Regular Market Volume 29,628
Return On Assets -0.83248
Return On Equity -4.50602
Sand P52 Week Change 0.34445214
Sector
Sector Key
Short Name Cingulate Inc. Warrants
Source Interval 15
State KS
Symbol CINGW
Total Cash 10,953,383
Total Cash Per Share 0.942
Total Debt 8,786,555
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.732
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 29,628
Website https://www.cingulate.com
Zip 66,205